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Abstract
Background: Ewing’s sarcoma is an aggressive bone and soft tissue tumor with a high incidence in children and
adolescents. Due to its high malignancy and poor prognosis, identification of novel biomarkers for intervention
therapies is necessary to improve outcome. The EWS/FLI1 fusion gene is a characteristic of Ewing’s sarcoma in most
cases. Sex determining region Y-box 2 (SOX2) is a primary target of EWS/FLI1. It has been identified as an oncogene
and linked to apoptotic resistance in several types of cancer. However, its role and regulatory mechanisms in
Ewing’s sarcoma are largely unknown.
Methods: We systematically investigated the role of SOX2 in Ewing’s sarcoma cell lines, human tissue samples and
xenograft models. The expression of SOX2 was detected in Ewing’s sarcoma samples by WB and IHC. siRNAs were
used to knockdown EWS/FLI1 and SOX2 in A673 and RD-ES cell lines with the efficiencies tested by qRT-PCR and
WB. The effect of SOX2 on cell cycle and apoptosis was determined by Flow cytometric and TUNEL assays. Akt
overexpression was performed with plasmid. The protein expression of the corresponding factors was examined by
WB analysis. Inhibition of SOX2 in vivo was performed by siRNA against SOX2 in xenograft models, and the protein
expression of the regulators testified in vitro was examined in xenograft tumors by IHC and WB.
Results: The results confirmed that SOX2 was highly expressed in Ewing’s sarcoma and was the target of EWS/FLI1.
SOX2 advanced Ewing’s sarcoma cell survival and proliferation by regulating p21, p27 and cyclin-E to facilitate G1/S
phase transition and mediating caspase-3, PARP via both extrinsic (Fas and caspase-8) and intrinsic (caspase-9, Bad,
Bcl-2 and XIAP) apoptotic pathways to restrain cell apoptotsis. Additionally, SOX2 regulated the cell-cycle
progression and apoptosis via activation of the PI3K/Akt signaling pathway. The mechanisms were proved both
in vitro and in vivo.
Conclusions: The results demonstrate that SOX2 played a central role in promoting Ewing’s sarcoma cell
proliferation in vitro and in vivo with the underlying mechanisms expounded. These findings suggest that SOX2
may serve as a potential biomarker for targeted intervention in Ewing’s sarcoma.
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Background
Ewing’s sarcoma is the second most common bone and
soft tissue malignancy after osteosarcoma with a high
incidence in children and adolescents [1, 2]. It is associ-
ated with rapid progression, a tendency to metastasize
and shows a high rate of recurrence after resection. Des-
pite advances in combinational therapies, the prognosis
of patients with Ewing’s sarcoma remains poor with low
survival rates [1, 3]. Therefore, identification of novel
biomarkers for target intervention is essential in order to
improve treatment outcomes.
Ewing’s sarcoma is characterized by unique chromo-
somal translocations; the most common is t(11;22)
(q24;q12) generating the EWS/FLI1 fusion gene that ac-
counts for 85 % of all cases [4, 5]. EWS/FLI1 encodes a
chimeric protein consisting of the transcriptional activa-
tion domain of EWS and the DNA-binding domain of
FLI1 [6, 7]. Recombination gives rise to an aberrant tran-
scriptional factor, believed to be implicated in the origin
of ESFT [8]. Transfection of EWS/FLI1 into mesenchy-
mal stem cells (MSC) revealed that EFTS cancer stem
cells (CSC) express genes associated with embryonic stem
cell (ESC), including SOX2, OCT4 and NANOG [9, 10].
Of these, SOX2 (sex determining region Y-box 2) was
identified as a key EWS/FLI1 target gene and shown to
participate in the progression of ESFT [11].
SOX2 is a critical transcriptional factor for self-
renewal and maintenance of undifferentiated ESCs, and
was initially selected for deriving induced pluripotent
stem (iPS) cells [12, 13]. Since its close association with
CSCs [11, 14–22], SOX2 has been reported as being
overexpressed in many aggressive tumors [23–29]. Its
role as an oncogene in malignant transformation has
been confirmed in multiple studies showing that it
could promote tumor cell growth [11, 15, 17, 22–28]
and advance tumorigenesis [11, 15, 19–21, 24]. SOX2
has been linked to apoptotic resistance [21, 23, 24, 26–28]
and shown to facilitate cell cycle progression [22–25, 27]
in certain types of cancers. For example, repression of
SOX2 was found to induce cell apoptosis via cleavage of
caspase-3 and activation of specific pro-apoptotic factors
[23, 24, 26], and inhibit G1/S transition by regulating
cyclin E in prostate cancer [23, 27] and cyclin D1 in breast
cancer [25]. In addition, SOX2 was identified as a regu-
latory factor in several key signaling pathways asso-
ciated with tumor progression, including the Akt,
Wnt and MAPK pathways [16, 19, 20, 23, 25–29].
Although SOX2 has been strongly implicated with
Ewing’s sarcoma cell proliferation and tumorigenesis,
the specific regulatory mechanisms remain unclear
[11]. Therefore, the purpose of this study was to
determine the role of SOX2 in the progression
of Ewing’s sarcoma and elucidate the underlying
mechanisms.
Methods
Unless otherwise stated, all solutions and materials were
standard analytical grade laboratory stocks. Experiments
were repeated as indicated in the figure legends for
statistical analysis.
Tissue specimens, cell lines and culture
Formalin-fixed paraffin-embedded (FFPE) specimens of
Ewing’s sarcomas and normal soft tissues around bones
were acquired from the Musculoskeletal Tumor Center,
Peking University People’s Hospital, Beijing, China. All
patients provided written informed consent and the
study was approved by the center’s Ethics Committee.
Human Ewing’s sarcoma cell lines A673 and RD-ES
(American Type Culture Collection; ATCC; Rockville,
MD, USA) were maintained in a humidified atmosphere
of 5 % CO2 at 37 °C in DMEM or RPMI-1640 medium,
respectively, supplemented with 10 % fetal bovine serum
(FBS; Hyclone, Logan, UT, USA) and streptomycin/
penicillin antibiotics.
Immunohistochemistry
Tissue specimens were sectioned (4 μm thickness) and
dewaxed in dimethylbenzene before being rehydrated
through an increasing ethanol gradient. The sections
were rinsed in PBS and incubated in 3 % hydrogen
peroxide for 15 min at room temperature. They were
blocked in 10 % goat serum for 30 min prior to incuba-
tion with rabbit polyclonal antibodies (1:100 dilution)
overnight at 4 °C followed by incubation with secondary
antibody for 1 h at room temperature. Diaminobenzidine
was added as a chromogen and the sections were
counterstained with hematoxylin. Positive staining was
defined as >10 % of cells appearing as brown granules.
Antibodies against SOX2 (3579), p-Akt (4060), cyclin-E
(4136) and cleaved-caspase-3 (9661) for immunohisto-
chemistry were purchased from Cell Signaling Technology
(Beverly, MA, USA).
Knockdown of genes with siRNAs and overexpression of
Akt with plasmids
SiRNAs were purchased from OriGene Technologies
(Rockville, MD, USA). Knockdown of genes was per-
formed using siRNAs against EWS/FLI1 (siEF [30, 31] and
siEF-bp [30, 32]) and SOX2 (siSOX2-#1 and siSOX2-#2).
A stable non-specific siRNA (siNC) was used as a negative












A673 and RD-ES cells were transfected at 50–60 % con-
fluence with 200 nmol/L siRNAs using Lipofectamine
2000 Transfection Kit (Life Technologies-Invitrogen;
Carlsbad, CA, USA) according to the manufacturer’s
protocol.
Overexpression of AKT was carried out using a GV219
plasmid (Genechem, Shanghai, China) carrying the AKT1
cDNA insert (NM_005163); an empty vector was used as
a negative control. Plasmids were transfected into cells at
90 % confluence using the Lipofectamine 2000 Transfec-
tion Kit according to the manufacturer’s protocol.
After 48 h transfection, cells were collected for further
analyses.
Real-time quantitative reverse transcription PCR (qRT-
PCR)
Total RNA was extracted using a PureLink RNA Mini
Kit (Ambion, Life Technologies). CDNA was synthesized
with purified RNA using SuperScript III First-Strand
Synthesis SuperMix (Invitrogen). Amplification was
performed using primers with SYBR GreenER qPCR
SuperMix Universal (Invitrogen). GAPDH was used as a
control. All protocols were performed according to the
manufactures’ instructions. The primer sequences were
as follows: EWS/FLI1, 5′-CGACTAGTTATGATCAG
AGCAGT-3′(forward) and 5′-CCGTTGCTCTGTATTC
TTACTGA-3′ (reverse); SOX2, 5′-CAGGAGTTGTC
AAGGCAGAGA-3′ (forward) and 5′-CAGGAGTTGTC
AAGGCAGAGA-3′ (reverse); GAPDH, 5′-ACAACTT
TGGTATCGTGGAAGG-3′ (forward) and 5′-GCCATC
ACGCCACAGTTTC-3′ (reverse). Reactions were per-
formed for 2 min at 50 °C, 10 min at 95 °C, followed by
40 cycles of 15 s at 95 °C and finally 30 s at 56 °C and
30 s at 72 °C.
Western blot assays and antibodies
Tissue samples and cells were lysed using RIPA lysis buf-
fer and centrifuged before collecting the supernatants.
Protein concentrations was evaluated by UV absorbance
(280 nm) and samples containing equal amounts of pro-
tein were separated on 8–12 % SDS-polyacrylamide gels
using a NuPAGE system (Invitrogen). Following separ-
ation, the proteins electrophoretically transferred onto
PVDF membranes and blocked in non-fat milk for 1 h.
The membranes were then incubated with primary anti-
bodies overnight at 4 °C followed by incubation with
HRP-conjugated secondary antibodies for 1.5 h at room
temperature. Immunoreactive bands were visualized and
quantified using an electrophoresis image analysis system
(Bio-Rad; Hercules, CA, USA).
Antibodies against SOX2 (3579, 1:1000), PI3K (11189,
1:500), p-Akt (9271, 1:500), Fas (4233, 1:500), Bad (9239,
1:500), Bcl-2 (2872, 1:1000), XIAP (2042, 1:1000),
Caspase-8 (9746, 1:500), Caspase-9 (9508, 1:1000),
Caspase-3 (9662, 1:1000), PARP (9542, 1:1000), Cyclin-E
(4129, 1:500) and Cyclin-D1 (2922, 1:1000) were
purchased from Cell Signaling Technology (Beverly,
MA, USA). Anti-Fli1 (sc-356, 1:500), anti-Akt (sc-8312,
1:500), anit-p21 (sc-271532, 1:500), anti-p27 (sc-71813,
1:500) and GAPDH (sc-365062 1:1000) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell viability and proliferation assays
The MTT cell viability assay was performed by plating
transfected cells into 96-well plates at a density of 3 ×
103 cells/well. The cells were incubated for 72 h prior to
adding MTT solution (Sigma-Aldrich; St. Louis, MO,
USA) and cultured for a further 4 h. The cells were lysed
with dimethyl sulfoxide (DMSO) and absorbance was
measured at 490 nm using a microplate reader (Molecular
Devices; Sunnyvale, CA, USA).
The colony formation assay was performed by plating
transfected cells at logarithmic growth phase into 6-well
plates at a concentration of 1 × 103 cells/well. Colonies
were allowed to form for 7 days before the cells were
fixed with ice-cold methanol and stained with crystal
violet solution. The numbers of colonies were counted
under a microscope: a colony was defined as a group
containing ≥10 cells.
Flow cytometric assays for cell cycle distribution and
apoptosis
The cell cycle assay was performed by fixing the cells in
70 % ethanol at 4 °C overnight and treated with 0.2 %
Triton X-100 and RNase before being stained with Pro-
pidium Iodide (PI) for 30 min in darkness. The cells
were analyzed using an Accuri C6 flow cytometer
(Accuri Cytometers Inc.; Ann Arbor, MI, USA) and the
percentages of cells at each phase of cell cycle were
determined.
The cell apoptosis assay was performed using an
Annexin-V/FITC Kit (BD Biosciences; San Jose, CA,
USA). Transfected-cells were collected and washed in
ice-cold PBS before being stained with Annexin V and
PI solution for 15 min in darkness. The ratios of apop-
totic cells were determined using an Accuri C6 flow
cytometer.
Cell cycle and apoptosis were analyzed by the flow
cytometer assays 48 h after transfection.
TUNEL assay of cell apoptosis
Cells were seeded onto slides and cultured before being
treated with appropriate siRNAs. The cells were then
fixed in 4 % paraformaldehyde for 60 min and
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permeabilized with 0.1 % Triton X-100 on ice for 2 min.
Cell apoptosis was determined using a TUNEL Apop-
tosis Assay Kit (Roche Applied Science; Mannheim,
Germany) according to the manufacturer′s instructions
48 h post transfection. Briefly, TUNEL (TdT-mediated
dUTP nick end labeling) reaction mixture was added to
the cells and the slides were rinsed in PBS before being
incubated in a humidified chamber at 37 °C for 60 min
in darkness. Anti-fluorescence quenching solution was
added before examining the cells under a confocal laser-
scanning microscope (TCS SP5) at an excitation wave-
length of 450–500 nm and an emission wavelength of
515–565 nm (green fluorescence) in order to evaluate
the proportions of apoptotic cells.
Xenograft tumorigenicity assays
BALB/c athymic mice at 6–8 weeks old were acquired
from Vital River (Beijing, China) and kept according to
animal welfare guidelines of Peking University People’s
Hospital. Each mouse was injected in the right flank
with 3 × 106 A673 Ewing’s sarcoma cells. When the
xenograft tumors were palpable, the mice were randomly
divided into three groups. For each group, intratumoral
injection with siSOX2, siNC or glucose was performed
once every 2 days. Five microgram siSOX2 or siNC was
mixed with 8 μl transfection reagent (Entranster-in vivo;
Engreen, Beijing, China) and hydrated with 10 % glucose
injection at a concentration of 50 μg/ml for each injec-
tion. The tumor volumes were calculated ([length ×
width2]/2) every 3 days and the data were plotted for
comparison. After 30 days, the mice executed humanely
and the tumors were excised and photographed. Xeno-
graft tissue samples were prepared for subsequent IHC
and Western blot assays.
Statistical analysis
All the statistical analyses were performed using SPSS
v.19.0 software (SPSS; Chicago, IL, USA). Independent
two-sample t-tests were used to compare differences
between two groups. One-way analysis of variance
(ANOVA) with the multiple comparison test was used
to analyze differences between three or more groups. All
data were presented as mean ± standard deviation based
on three independent experiments. A P-value <0.05 was
considered statistically significant.
Results
SOX2 was a downstream target of EWS/FLI1 in Ewing’s
sarcoma cells
In order to confirm the relationship between SOX2 and
EWS/FLI1 in Ewing’s sarcoma, two small interfering
RNAs (siRNAs) were used to knockdown EWS/FLI1 in
A673 and RD-ES cells. The knockdown efficiencies were
determined for mRNA and protein expressions by real-
time quantitative reverse transcription PCR (qRT-PCR)
and Western blot assays, respectively. The results
showed that expression of EWS/FLI1 was downregulated
at both mRNA and protein levels in the transfected cells,
with a concurrent reduction in the expression of SOX2
(Fig. 1a and b; P < 0.001). These results confirmed that
SOX2 was a downstream regulatory target of EWS/FLI1
in Ewing’s sarcoma cells.
SOX2 was highly expressed in Ewing’s sarcoma tissue
samples
Expressions of SOX2 protein in human tissue samples
acquired from Ewing’s sarcomas and normal tissues
around bones were determined by Western blot and
immunohistochemistry (IHC) assays. Western blotting
showed that protein expression of SOX2 was markedly
higher in Ewing’s sarcoma samples compared to levels in
normal tissues (Fig. 1c; P < 0.001). Similar results were
obtained by IHC, as indicated by positive staining in
sarcoma tissues and negative staining in normal tissues
(Fig. 1d). These results implied that SOX2 played a key
role in Ewing’s sarcoma.
Knockdown of SOX2 inhibited cell viability and growth in
Ewing’s sarcoma in vitro
In order to determine whether overexpression of SOX2
advanced the growth capacity of Ewing’s sarcoma cells,
two different siRNAs against SOX2 were used to knock-
down expression of SOX2 in A673 and RD-ES cell lines.
Expression levels were compared to those in controls
that had been treated without siRNA and negative con-
trols (siNC). Both SOX2 mRNA and protein expressions
were significantly downregulated in the silenced cells
(siSOX2-#1 and siSOX2-#2) compared to control cells
(Fig. 2a and b, respectively; P < 0.001). The most effective
siRNA (siSOX2-#1;P < 0.01 to P <0.001) was the selected
for use in subsequent experiments.
The MTT cell viability assays showed that knockdown
of SOX2 reduced cell viability by approximately 30 % in
both cell lines compared to controls (Fig. 2c; P < 0.001).
Furthermore, knockdown of SOX2 suppressed the colony
forming ability of the cell lines (Fig. 2d; P < 0.001).
Suppression of SOX2 induced G1/S cell cycle arrest by
targeting cyclin-E, p21 and p27
The effect of SOX2 knockdown on cell cycle distribution
in Ewing’s sarcoma cells was investigated by flow cytom-
etry in A673 and RD-ES cell lines as an indication of
proliferative capacity. The results showed a significant
increase in the percentage of SOX2-knockdown cells at
G0/G1 phase compared to control cells, with a concur-
rent decrease in the proportion of cells at S and G2/M
phases (Fig. 3a and b; P < 0.001). This indicated that
silencing SOX2 induced cell cycle arrest at G1/S phase.
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To explore the potential mechanism, the protein
expressions of four critical regulators of G1/S transition
(cyclin-D1, cyclin-E, p21cip1 and p27kip1) [33–36] were
analyzed by Western blotting. Expressions of cyclin-
dependent kinase (CKD) inhibitors p21 and p27 were
markedly increased after knockdown of SOX2 compared
to control cells; expression of cyclin-E was decreased;
however, there was no significant change in expression
of cyclin-D1 (Fig. 3c). Cyclin-E binds CDK2 to induce
G1/S transition [33, 34], whereas p21 and p27 repress
cyclin-E/CDK2 complex to inhibit the processes [35, 36];
therefore these results indicated that inhibition of SOX2
in Ewing’s sarcoma cells was induced by repression of
cyclin-E and activation of p21 and p27.
Inhibition of SOX2 promoted cell apoptosis in Ewing’s
sarcoma via activation of extrinsic and intrinsic apoptotic
pathways
To investigate whether knockdown of SOX2 induced apop-
tosis in Ewing’s sarcoma cells, flow cytometric and TUNEL
assays were performed in A673 and RD-ES cell lines. Flow
cytometric analysis showed that the proportions of early
and late apoptotic cells were significantly increased by silen-
cing SOX2 in both cell lines compared to those in controls
(Fig. 4a and b; P < 0.001). Similarly, the TUNEL assay
showed an increase in apoptotic cells, as evidenced by
enhanced fluorescence, in both cell lines following knock-
down of SOX2, confirming that inhibition of SOX2
induced apoptosis in Ewing’s sarcoma cells (Fig. 4c).
Fig. 1 SOX2 was regulated by EWS/FLI1 and highly expressed in Ewing’s sarcoma. a, and b Expression of SOX2 was significantly decreased by
EWS/FLI1 knockdown in A673 and RD-ES cells in terms of both on mRNA and protein levels. Data are representative of three independent
experiments. c SOX2 was expressed in Ewing’s sarcoma but not in normal tissues around bones examined by WB analysis. d Representative
images of IHC staining of SOX2 in normal tissues and Ewing’s sarcoma. All data are presented as means ± S.D. **P < 0.001
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To elucidate the potential mechanism, two key regula-
tors of cell apoptosis, caspase-3 and poly ADP ribose
polymerase (PARP), were examined by Western blotting.
PARP plays a central role in DNA repair; however, cleav-
age of PARP results in loss-of-function and can be
induced following activation of caspase-3 via cleavage
[37]. The analyses showed that transfection with siSOX2
resulted in marked increases in cleavages of caspase-3
and PARP following compared to the levels in control
cells (Fig. 4d).
To further explore the molecular mechanism under-
lying, Western blotting was used to determine the
protein expressions of specific apoptotic mediators (cas-
pase-8, caspase-9, Fas, Bad, Bcl-2 and XIAP). Caspase-3
is the downstream target of caspase-8 and caspase-9
[38]; caspase-8 is a key protein in extrinsic apoptotic
pathways and is stimulated by cell surface death recep-
tors, such as Fas [38, 39]; caspase-9 is a key protein in
intrinsic apoptotic pathways activated by mitochondrial
dysfunction, which involved Bcl-2 family proteins, like
Bad and Bcl-2 [38, 40]; and XIAP is an anti-apoptotic
protein inhibiting caspase-3 and −9 [38, 41]. The results
showed that caspases-8 and −9 were fully activated, as
evidenced by complete cleavage of both proteins, with
Fig. 2 SOX2 knockdown by siRNA inhibited the growth capacity of Ewing’s sarcoma cells. a, and b The mRNA and protein expression levels of
SOX2 were significantly repressed by the transfection of SOX2 siRNA in both A673 and RD-ES cells. c The cell viabilities were inhibited in both cell
lines after SOX2 knockdown according to the MTT assay. d SOX2 inhibition resulted in a decreased colony formation capacity in both A673 and
RD-ES cell lines. Representative pictures were displayed and the colonies per area were shown as data in bars. All data are presented as means ±
S.D. *P < 0.01, **P < 0.001
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concurrent elevation of pro-apoptotic proteins Bad and
Fas; whereas expressions of anti-apoptotic proteins Bcl-2
and XIAP were substantially decreased compared to
controls (Fig. 4e). These results indicated that inhibition
of SOX2 induced activation of both extrinsic cell death
receptor and intrinsic mitochondrial apoptotic pathways,
leading to apoptosis in Ewing’s sarcoma cells.
SOX2 regulated cell-cycle progression and apoptosis in
Ewing’s sarcoma via activation of the PI3K/Akt signaling
pathway
The PI3K/Akt signaling pathway plays an essential role in
cell survival and cell growth via direct or indirect regula-
tion of apoptotic factors and cell cycle regulators, includ-
ing those identified as targets of SOX2 in our previous
analyses (caspase-9, Bad, Fas, p21, p27) [42–45]. This
suggested a functional relationship between SOX2 and the
PI3K/Akt signaling pathway in Ewing’s sarcoma cells.
To verify this supposition, the expressions of PI3K,
Akt and p-Akt proteins in A673 and RD-ES cells follow-
ing knockdown of SOX2 were examined by Western
blotting. The results showed marked reductions in PI3K
and Akt protein expression levels with an almost
complete loss of p-Akt expression compared to the con-
trols (Fig. 5a). These findings confirmed that SOX2 was
an upstream mediator in the PI3K/AKT signaling path-
way in Ewing’s sarcoma cells. To further demonstrate
that SOX2 was implicated in the proliferation and pro-
gression of Ewing’s sarcoma, we reactivated the PI3K/
Akt pathway after knockdown of SOX2 by overexpress-
ing Akt using plasmids. Western blotting was performed
to confirm that the expressions of Akt and p-Akt pro-
teins were raised by Akt overexpression (Fig. 5b). Four
Fig. 3 SOX2 inhibition induced G1/S cell cycle arrest. a, and b The cell cycle was assayed by flow cytometry. The percentages of cell cycle phases
were displayed in bar charts. siSOX2 transfection resulted in a significant increase of the cells proportion in the G0/G1 phases of A673 and RD-ES
cells. c SOX2 inhibition amplified the expression of p21 and p27, and repressed cyclin-E, but had no effect on cyclin-D expression in Ewing’s
sarcoma cells according to assayed by WB analyses. The data are representative and selected from one of three independent experiments
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Fig. 4 SOX2 knockdown promoted the apoptosis of Ewing’s sarcoma cells by activating the extrinsic and intrinsic apoptotic pathways. a, and
b Cell apoptosis analysis was performed by flow cytometry. The bar charts showed the significant increases in the early and late apoptotic
indexes of A673 and RD-ES cells transfected with siSOX2. c Cell apoptosis of A673 and RD-ES cells treated with siSOX2 were evaluated by the
TUNEL assay. d Cleavage of caspase-3 and PARP were enhanced in Ewing’s sarcoma cells transfected with siSOX2, as assayed by WB. e The proteins of
the cell death receptor and mitochondrial apoptosis pathways were examined by WB assays in cells under SOX2 knockdown conditions performed.
SOX2 inhibition amplified pro-apoptotic regulators, such as Fas and Bad, repressed anti-apoptotic mediators, such as Bcl-2 and XIAP, and activated
caspases-8 and caspase-9. The data are representative of three independent experiments
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test groups were prepared: untreated controls (−/−),
SOX2 knockdown (+/−), Akt overexpression (−/+), and
cotransfection of siSOX2 + Akt plasmid (+/+). Knock-
down of SOX2 resulted in complete loss of p-Akt pro-
tein expression, as previously demonstrated; however, in
the contransfected group, this was counteracted by over-
expression of Akt resulting in the recovery of p-Akt to
its untreated levels. The Akt overexpression group
showed increases of Akt and p-Akt protein but no sig-
nificant changes of SOX2 protein expression (Fig. 5c).
Inhibition of Akt phosphorylation through knock-
down of SOX2 was found to elevate protein expres-
sions of pro-apoptotic factors Bad and Fas, induce
cleavage of caspase-9 and caspase-3, promote expres-
sion of p21 and p27, and suppress expression of
cyclin-E compared to the corresponding levels in
untreated controls. Recovery of p-Akt through overex-
pression of Akt negated these effects in the cotrans-
fection group (Fig. 5d).
These findings indicated that regulation of apoptotic
and G1/S transitional factors in Ewing’s sarcoma cells
were induced by SOX2 via activation of the PI3K/Akt
pathway.
Suppression of SOX2 inhibited tumorigenesis in Ewing’s
sarcoma in vivo
To confirm our in vitro findings in vivo, Ewing’s sar-
coma xenograft models were established in mice. The
mice received intramural injections of siSOX2 (siSOX2
group), glucose (mock control group) or siNC (negative
control group). The results showed that rate of tumor
growth and the sizes of the tumors were significantly
lower in the siSOX2 group compared to those in the
control groups (Fig. 6a and b; P < 0.001). These findings
confirmed that inhibition of SOX2 could significantly re-
press tumorigenesis in Ewing’s sarcoma in vivo.
In order to determine whether the proteins identified
as influencing cell cycle transition and apoptosis in the
in vitro experiments were observed in vivo, IHC and
Western blot assays were performed using tissue sam-
ples from the xenograft models. As observed in vitro,
the results confirmed that SOX2 regulated apoptotic and
Fig. 5 SOX2 was found to regulate cell cycle and apoptosis of Ewing’s sarcoma cells via the PI3K/Akt signaling pathway. a WB assay showed
SOX2 knockdown resulted in decreased expressions of PI3K and Akt and the loss of p-Akt in A673 and RD-ES cells. b Overexpression of Akt was
evaluated by WB analysis. c Four groups were designed for Ewing’s sarcoma cells as mock control, SOX2 knockdown, Akt overexpression and the
contransfection of siSOX2 and Akt plasmids. Expression levels of SOX2, Akt and p-Akt of the four groups were examined by WB. d Further investigation
of the proteins targeted by SOX2 and Akt involved in the Ewing’s sarcoma cells apoptosis and G1/S transition, including Fas, Bad, caspase-9,
caspase-3, p21, p27 and cyclin-E, were analyzed by WB in the four designed groups. Representative data from one of three independent
experiments are exhibited in (a–d)
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cell cycle factors via mediation of PI3K/Akt signaling:
IHC showed that positive staining for pro-proliferation
factors (SOX2, p-Akt and cyclin-E) was lower in xeno-
graft tissues from the siSOX2 group compared to those
from the siNC group. In contrast, positive staining for
pro-apoptotic cleaved-caspase-3 was higher in xenograft
samples from the siSOX2 group compared to that in the
siNC group (Fig. 6c). Western blotting revealed that xe-
nografts treated with siSOX2 had reduced expressions of
PI3K and Akt proteins and almost no expression of
p-Akt compared to the corresponding levels in the siNC
group. This confirmed that silencing SOX2 inhibited
PI3K/Akt signaling in vivo. Similarly, silencing SOX2
elevated protein expressions of pro-apoptotic factors Fas
and cleaved-caspase-8 (mediators in the cell death re-
ceptor pathway), Bad and cleaved-caspase-9 (mediators
in the mitochondrial apoptotic pathway), as well as
cleaved-caspase-3 (activated by the cell death receptor
Fig. 6 SOX2 inhibition suppressed Ewing’s sarcoma growth in vivo. a Tumor growth was significantly repressed by siSOX2 intratumoral injection
as shown in the curve graph (Data are presented as the mean ± S.D. **P < 0.001). b SOX2 inhibition substantially decreased xenograft tumor
volume, shown as representative images exhibited. c Representative images of IHC analysis demonstrated the significant repression of SOX2,
p-Akt and cyclin-E, and the enhancement of cleaved-caspase-3 in tumor samples treated with siSOX2. d Variations of the upstream regulators,
such as SOX2, PI3K, Akt and p-Akt, the downstream anti-survival of proteins, such as Fas, caspase-8, Bad, caspase-9, caspase-3, p21 and p27, and
the pro-proliferation factors, such as PARP and cyclin-E, were all followed the same trends described as in vitro, as analyzed by WB. The data are
representative of three independent experiments
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and mitochondrial apoptotic pathway) and cleaved-
PARP, demonstrating that SOX2 inhibition induced cell
apoptosis. In addition, protein expressions of cell cycle
regulators p21 and p27 were increased after injection of
siSOX2, whereas expression of cyclin-E was decreased,
indicating that knockdown of SOX2 suppressed G1/S
phase transition (Fig. 6d).
Together, these results verified that SOX2 promoted
tumor cell proliferation in Ewing’s sarcoma by restrain-
ing apoptosis and promoting cell cycle progression via
the PI3K/Akt pathway both in vitro and in vivo (Fig. 7).
Discussion
Ewing’s sarcoma is characteristic with aberrant fusion
genes formed by chromosomal translocations, in which
EWS/FLI1 is the most common [4, 5]. SOX2, a key regu-
lator of pluripotency in ESCs, was initially linked to
Ewing’s sarcoma by the observation that MSCs trans-
fected with EWS/FLI1 displayed features of ESFT CSCs
[9, 10]. The combination of EWS transactivation domain
and the FLI1 DNA-binding domain give rise to hetero-
geneous breakpoints, the most common being type1
(Exon 7 of EWS/Exon 6 of FLI1) and type2 (Exon 7 of
EWS/Exon 5 of FLI1) [4, 6, 32, 46, 47]. These two break-
points are respectively present in the A673 and RD-ES
cell lines used in our study. Consistent with previous
reports, we found that silencing EWS/FLI1 in these cell
lines with siRNAs significantly suppressed expression of
SOX2, verifying that SOX2 was a downstream target of
EWS/FLI1. Furthermore, this study has provided the
first evidence that the mechanism involved both the two
EWS/FLI1 breakpoints.
In addition to being essential for maintaining cell
stemness, SOX2 has been identified as an oncogenic
factor in processes associated with tumor progression
including cell proliferation and tumorigenesis of ESFT
[11]; however, details of the mechanism are poorly
understood. Based on our observation that expression of
SOX2 was higher in Ewing’s sarcoma tissues compared
to normal tissues around the bones, we hypothesized
that downregulation of SOX2 might suppress malignant
activity in Ewing’s sarcoma.
SOX2 has been reported to facilitate G1/S transition
as a mechanism to promote tumor progression in
several types of neoplasms, including prostate and
breast cancers and some cancers of the digestive sys-
tem [22–25, 27]. In agreement with these reports, we
demonstrated that silencing SOX2 with siRNAs re-
sulted in an accumulation of cells at G0/G1 phase
leading to G1/S cell cycle arrest. Further analysis
demonstrated that this was mediated through regula-
tion of key cell cycle regulators: cylin-D1 and cyclin-E
bind cyclin-dependent kinases (CDKs) to induce tran-
sition from G0/G1 to S phase [33, 34]; whereas p21
and p27 act as CDK inhibitors [35, 36]. Our results
indicated that SOX2 promoted G1/S transition via
regulation of cyclin-E, p21 and p27, supporting previ-
ous reports that SOX2 plays a central role in tumor
cell proliferation in Ewing’s sarcoma.
Previous studies have reported that SOX2 increased
apoptotic resistance in several types of malignancies and
Fig. 7 Schematic of the detailed molecular mechanism of SOX2 in regulating cell proliferation of Ewing’s sarcoma in vitro and in vivo
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CSCs [21, 23, 24, 26, 27]. Consistent with these reports,
we found that silencing SOX2 resulted in morphologic
changes and a significant increase in apoptotic cells in
Ewing’s sarcoma. Moreover, the mechanism involved
activation of caspase-3 and subsequent amplification of
PARP cleavage. PARP plays an important role in DNA
repair and can be cleaved by activated capase-3 resulting
in cell apoptosis [37].
Further analyses into potential mechanisms revealed
that SOX2 possessed regulatory roles in both extrinsic
and intrinsic apoptotic pathways. The extrinsic cell death
receptor pathway is stimulated by receptors such as Fas
and activates caspase-8 [38, 39]; whereas Bcl-2 family
proteins are the principle regulators in the intrinsic
mitochondrial apoptosis pathway [38, 40]; caspase-9 is
pivotal in mitochondrial apoptotic processes and activa-
tion of casapse-3 by caspase-8 and caspase-9 initiates
cell apoptosis [38]. Our observations confirmed that
these actions were replicated in Ewing’s sarcoma: silen-
cing SOX2 promoted apoptosis in Ewing’s sarcoma cells
via activation of caspase-8 and caspase-9, and stimulated
pro-apoptotic factors while repressing anti-apoptotic
factors in both the extrinsic and intrinsic pathways.
As a criterion for cell apoptosis assay, however, subG1
phase was not significantly detected in our cell cycle
analysis. It could be explained by the reason that DNA
fragments were not totally out of the cell membrane
and/or subG1 and G0/G1 phases were not sufficiently
separated. Similar results were exhibited in some re-
search showing cell apoptosis with no significant subG1
phase under SOX2 silencing [23, 24, 26]. Therefore, we
utilized TUNEL and Annexin-V/FITC assays to demon-
strate the cell apoptosis, which were much more suffi-
cient and persuasive than subG1 in cell apoptosis
investigation.
The role of SOX2 as a transcriptional regulator in critical
signaling pathways has been implicated in malignant pro-
gressions in various human cancers [16, 19, 20, 23, 25–28].
Of these, the Akt signaling pathway is considered to have
the greatest influence on cell cycle progression and apop-
tosis [42, 43]. Activation of Akt via phosphorylation has
been shown to directly downregulate pro-apoptotic pro-
teins, such as Bad and caspase-9, indirectly mediate the Fas
death receptor [43, 44], and target CDK inhibitors involved
in cell cycle regulation, including p21 and p27 [43, 45],
thereby promoting cell survival and growth. The present
study identified SOX2 as an upstream regulator in the
PI3K/Akt pathway in Ewing’s sarcoma; knockdown of
SOX2 reduced expression of PI3K and abolished
phosphorylation of Akt to p-Akt in vitro; whereas
overexpression of Akt counteracted the variations of
downstream proteins caused by silencing of SOX2,
thereby negating the effects of SOX2 inhibition on
the cell cycle progression and apoptosis. However,
SOX2 has not been categorically associated with any
classical pathway; therefore, it is unclear whether it reg-
ulates Akt via gene transcription or molecular mediation.
In addition, previous studies have reported that SOX2
serves as a downstream target of Akt in various malignan-
cies [16, 19, 23]. So, further investigation is warranted to
determine whether loop regulation of SOX2 and Akt
exists in Ewing’s sarcoma.
Having verified that SOX2 played significant roles
in Ewing’s sarcoma cell proliferation and identified
some of the underlying regulatory mechanisms in
vitro, it was necessary to confirm these findings in
vivo. By establishing Ewing’s sarcoma xenograft
models in mice, we were able to demonstrate that
treatment with siRNAs against SOX2 could substan-
tially reduce tumor growth of Ewing’s sarcoma in
vivo. Furthermore, variations of the factors that had
been identified in vitro, including SOX2, regulators of
the PI3K/Akt signaling pathway, apoptotic proteins
and G1/S transitional mediators, were also verified in
xenograft tissue samples.
Conclusion
In conclusion, our in vitro and in vivo data provided
comprehensive evidence that SOX2 played a central
role in promoting Ewing’s sarcoma cell survival and
proliferation. As a primary target of the EWS/FLI1
fusion gene characteristic of Ewing’s sarcoma, SOX2
facilitated G1/S phase transition through regulation of
key cell cycle factors and restrained cell apoptosis by
regulating apoptotic factors in both intrinsic and ex-
trinsic pathways via activation of the PI3K/Akt signal-
ing pathway. These findings have identified SOX2 as
a potential candidate biomarker for targeted interven-
tion in Ewing’s sarcoma and have provided an experimental
basis for future investigations.
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